ABOUT AJPP

The African Journal of Pharmacy and Pharmacology (AJPP) is published weekly (one volume per year) by Academic Journals.

African Journal of Pharmacy and Pharmacology (AJPP) is an open access journal that provides rapid publication (weekly) of articles in all areas of Pharmaceutical Science such as Pharmaceutical Microbiology, Pharmaceutical Raw Material Science, Formulations, Molecular modeling, Health sector Reforms, Drug Delivery, Pharmacokinetics and Pharmacodynamics, Pharmacognosy, Social and Administrative Pharmacy, Pharmaceutics and Pharmaceutical Microbiology, Herbal Medicines research, Pharmaceutical Raw Materials development/utilization, Novel drug delivery systems, Polymer/Cosmetic Science, Food/Drug Interaction, Herbal drugs evaluation, Physical Pharmaceutics, Medication management, Cosmetic Science, pharmaceuticals, pharmacology, pharmaceutical research etc. The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in AJPP are peer-reviewed.

Contact Us

Editorial Office: ajpp@academicjournals.org
Help Desk: helpdesk@academicjournals.org
Website: http://www.academicjournals.org/journal/AJPP
Submit manuscript online http://ms.academicjournals.me/
Editors

Himanshu Gupta
Department of Pharmacy Practice
University of Toledo
Toledo, OH
USA.

Prof. Zhe-Sheng Chen
College of Pharmacy and Health Sciences
St. John’s University
New York,
USA.

Dr. Huma Ikram
Neurochemistry and Biochemical
Neuropharmacology Research Unit,
Department of Biochemistry,
University of Karachi
Karachi-75270
Pakistan

Dr. Shreesh Kumar Ojha
Molecular Cardiovascular Research Program
College of Medicine
Arizona Health Sciences Center
University of Arizona
Arizona,
USA.

Dr. Vitor Engracia Valenti
Departamento de Fonoaudiologia
Faculdade de Filosofia e Ciências,
UNESP
Brazil.

Dr. Caroline Wagner
Universidade Federal do Pampa
Avenida Pedro Anunciação
Brazil.

Associate Editors

Dr. B. Ravishankar
SDM Centre for Ayurveda and Allied Sciences,
SDM College of Ayurveda Campus,
Karnataka
India.

Dr. Natchimuthu Karmegam
Department of Botany,
Government Arts College,
Tamil Nadu,
India.

Dr. Manal Moustafa Zaki
Department of Veterinary Hygiene and
Management
Faculty of Veterinary Medicine,
Cairo University
Giza,
Egypt.

Prof. George G. Nomikos
Takeda Global Research & Development Center
USA.

Prof. Mahmoud Mohamed El-Mas
Department of Pharmacology,
Faculty of Pharmacy
University of Alexandria,
Alexandria,
Egypt.

Dr. Kiran K. Akula
Electrophysiology & Neuropharmacology Research Unit
Department of Biology & Biochemistry
University of Houston
Houston, TX
USA.
**Editorial Board**

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof. Fen Jicai</td>
<td>School of life science, Xinjiang University, China.</td>
</tr>
<tr>
<td>Dr. Ana Laura Nicoletti Carvalho</td>
<td>Av. Dr. Arnaldo, 455, São Paulo, SP, Brazil.</td>
</tr>
<tr>
<td>Dr. Ming-hui Zhao</td>
<td>Professor of Medicine, Director of Renal Division, Department of Medicine, Peking University First Hospital, Beijing 100034, PR. China.</td>
</tr>
<tr>
<td>Prof. Ji Junjun</td>
<td>Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, China.</td>
</tr>
<tr>
<td>Prof. Yan Zhang</td>
<td>Faculty of Engineering and Applied Science, Memorial University of Newfoundland, Canada.</td>
</tr>
<tr>
<td>Dr. Naoufel Madani</td>
<td>Medical Intensive Care Unit, University hospital Ibn Sina, University Mohamed V, Rabat, Morocco.</td>
</tr>
<tr>
<td>Dr. Dong Hui</td>
<td>Department of Gynaecology and Obstetrics, the 1st hospital, NanFang University, China.</td>
</tr>
<tr>
<td>Prof. Ma Hui</td>
<td>School of Medicine, Lanzhou University, China.</td>
</tr>
<tr>
<td>Prof. Gu Huijun</td>
<td>School of Medicine, Taizhou University, China.</td>
</tr>
<tr>
<td>Dr. Chan Kim Wei</td>
<td>Research Officer, Laboratory of Molecular Biomedicine, Institute of Bioscience, Universiti Putra, Malaysia.</td>
</tr>
<tr>
<td>Dr. Fen Cun</td>
<td>Professor, Department of Pharmacology, Xinjiang University, China.</td>
</tr>
<tr>
<td>Dr. Sirajunnisa Razack</td>
<td>Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.</td>
</tr>
<tr>
<td>Prof. Ehab S. EL Desoky</td>
<td>Professor of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.</td>
</tr>
<tr>
<td>Dr. Yakisich, J. Sebastian</td>
<td>Assistant Professor, Department of Clinical Neuroscience, Karolinska University Hospital, Huddinge, 141 86 Stockholm, Sweden.</td>
</tr>
<tr>
<td>Prof. Dr. Andrei N. Tchernitchin</td>
<td>Head, Laboratory of Experimental Endocrinology and Environmental Pathology, University of Chile Medical School, Chile.</td>
</tr>
<tr>
<td>Dr. Sirajunnisa Razack</td>
<td>Department of Chemical Engineering, Annamalai University, Annamalai Nagar, Tamilnadu, India.</td>
</tr>
<tr>
<td>Dr. Yasar Tatar</td>
<td>Marmara University, Turkey.</td>
</tr>
<tr>
<td>Dr. Nafisa Hassan Ali</td>
<td>Assistant Professor, Dow Institute of Medical Technology, Dow University of Health Sciences, Chand bbi Road, Karachi, Pakistan.</td>
</tr>
<tr>
<td>Dr. Krishnan Namboori P. K.</td>
<td>Computational Chemistry Group, Computational Engineering and Networking, Amrita Vishwa Vidyapeetham, Amritanagar, Coimbatore-641 112, India.</td>
</tr>
<tr>
<td>Prof. Osman Ghani</td>
<td>University of Sargodha, Pakistan.</td>
</tr>
<tr>
<td>Dr. Liu Xiaoji</td>
<td>School of Medicine, Shihezi University, China.</td>
</tr>
</tbody>
</table>
Antihyperglycemic and antihyperlipidemic activities of ethanol extract of *Ajuga remota* Benth (Harmegusa) leaves in streptozotocin induced diabetic rats
Freshet Assefa, Daniel Seifu and Eyasu Makonnen

Determination of bioactive constituents of *Rauwolfia vomitoria* Afzel (Asofeyeje) roots using gas chromatography-mass spectrometry (GC-MS) and Fourier transform infrared spectrometry (FT-IR)
Okereke, S. C., Ijeh, I. I. and Arunsi, U. O.

Screening of some pyrazole derivatives as promising antileishmanial agent
Abdu Tuha, Adnan A. Bekhit and Yimer Seid
Antihyperglycemic and antihyperlipidemic activities of ethanol extract of *Ajuga remota* Benth (Harmegusa) leaves in streptozotocin induced diabetic rats

Freshet Assefa¹¹, Daniel Seifu² and Eyasu Makonnen³

¹Biochemistry Unit, School of Medicine, Hawassa University, Hawassa, Ethiopia.
²Biochemistry Department, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
³Pharmacology Department, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Received 9 November 2016; Accepted 21 December 2016

The leaves of *Ajuga remota* benth have been utilized traditionally for the treatment of patients with diabetes mellitus. However, its use has not been scientifically validated. The present study was therefore, aimed to assess the antihyperglycemic and antihyperlipidemic activities of ethanol extract of *A. remota* leaves in streptozotocin (STZ) induced diabetic rats. Antihyperglycemic and antihyperlipidemic activities of ethanol extract of *A. remota* leaves (AREt) were studied in streptozotocin induced diabetic rats. The effect of extract on fasting blood glucose, body weight, lipid profile, serum, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, urea, creatinine and total protein were analyzed. Glibenclamide was used as standard drug. Ethanol extract of *A. remota* leaves has showed significant blood glucose lowering effect as compared to the diabetic control group. After diabetic rats were treated with 200 and 400 mg/kg ethanol extract of *A. remota* leaves for 28 days, there were a significant decrease in fasting blood glucose, total cholesterol, triacylglycerol, low density lipoprotein cholesterol, serum alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase, and significant increase in body weight, serum total protein, high density lipoprotein cholesterol levels as compared to untreated control diabetic rats. The results of the present study showed that ethanol extract of *A. remota* leaves might be useful for management of diabetes mellitus and other associated abnormalities. The present study might support the traditional use of *A. remota* for diabetes mellitus treatment.

**Key words:** *Ajuga remota* benth, diabetes mellitus, streptozotocin.

**INTRODUCTION**

Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia with deranged carbohydrates, fats and proteins metabolism resulting from absolute or relative lack of insulin secretion or insulin resistance by peripheral tissues mainly the liver, skeletal muscle and adipose tissues. It is also characterized by hyperlipidemia and hyperaminoacidemia (Rao et al., 2010; Sudha et al., 2011). The long-term effects of diabetes mellitus include...
progressive development of retinopathy with potential blindness, nephropathy which may lead to renal failure, and/or neuropathy with risk of foot ulcers, amputation and features of autonomic dysfunction. People with diabetes mellitus are at increased risk of cardiovascular, peripheral vascular and cerebrovascular disease (Karimulla et al., 2011).

The global prevalence of diabetes mellitus was estimated to be 9% among adults aged 18 and above in 2014. In 2012, an estimated 1.5 million deaths were directly caused by diabetes. Currently, more than 80% of diabetes deaths occur in low- and middle-income countries. In Ethiopia, the prevalence of diabetes mellitus was 800,000 in the year 2000 and expected to reach 1.8 million by 2030 (Feleke and Enquselassie, 2005).

Modern antidiabetic drugs have their own limitations like high cost and effects such as hypoglycemia, weight gain, gastrointestinal disturbances, and liver toxicity (Dey et al. 2002). The use of plants as medicine dates back to early man. It is estimated that 70 to 80% of people worldwide rely on traditional herbal medicine to meet primary health care needs (Seifu et al., 2012). To date, ethnobotanical information indicates that over 1200 plants are used as traditional remedies for treatment of diabetes mellitus (Fraser et al., 2007) and more than 200 pure compounds have shown blood glucose lowering activities. WHO has encouraged and recommended the use of herbs as an alternative therapy for diabetes mellitus since medicinal plants are often less expensive, easily accessible, less toxic and suitable (Ansarullah et al., 2011).

*A. remota* (Figure 1) is a herb that belongs to Lamiaceae family, and is locally known as ‘harmegusa’ or ‘ete- medihanit’. It often lies on the ground and its stems grow to 40 cm high. It grows in different regions of Ethiopia at an altitude of 1600 to 2200 m, flowering from September to October (Dagne, 2009).

Phytochemical investigations of *A. remota* showed the presence of neo-Clerodane diterpenoids (Coll and Tandrón 2005), phytoecdysteroids (Kubo et al., 1983), phenolics, flavonoids, glycosides and sugars are major constituents (Debella et al., 2005). Its leaves are known to relieve stomachache, cold, fever and gonorrhea (Githinji and Kokwaro, 1993). It has been reported that *A. remota* is antimalarial (Gitua et al., 2012). Its aerial parts had some potent antimycobacterial (Cantrell et al., 1999), analgesic and antipyretic activity (Debella et al., 2005). In Ethiopia, the leaves of *A. remota* benth are used for diabetes mellitus treatment by traditional healers. The present study aimed to determine the antihyperglycemic and antihyperlipidemic activities of 70% ethanolic leaves extract of *A. remota* benth in diabetic rats.

**METHODS**

**Chemicals and equipment**

In this study, the following drugs, reagents and instruments were used: streptozotocin (Sigma Aldrich, Germany), glibenclamide (Sanofi Winthrop Industrie, France), SensoCard glucometer and strip (77 Electronike Kft, Hungary) and 902 automated chemistry analyzer (Hitachi, Japan). All other chemicals used were analytical grade.

**Collection and preparation of plant material**

Fresh leaves of *A. remota* were collected from Deneba town, North Shoa about 175 km North-East of Addis Ababa in late September, 2012. The leaves were identified and authenticated by the National Herbarium (ETH) of Addis Ababa University, and voucher number 001 was given and deposited at the same institute for further reference. The dried leaves were manually grinded and the coarse powder was kept in polyethylene bags at room temperature until used for extraction.

**Experimental animals**

Adult male Wistar albino rats of body weight 150 to 230 g (initial) with no prior drug treatment were used for the study. Rats were purchased from Ethiopian Public Health Institute (EPHI). All the rats were acclimatized to the laboratory condition for one week before commencing the experiments and fed with pellet and tap water ad libitum. The animals were housed in 12 h light and dark cycle at room temperature (20 to 25°C). The experiment was performed in the laboratory of Pharmacology Department, School of Medicine, Addis Ababa University. All animals employed in this study were handled as per the guidelines set by the national academies press, Washington, D.C., USA.

**Extraction**

The coarse powder (600 g) of *A. remota* leaves was macerated in 70% ethanol (1:10 leaves powder to solvent ratio) for 72 h with mechanical shaking twice a day. This was repeated three times until the extract gave faint or no coloration. The extract was then filtered through Whatman filter paper No.1 and evaporated to dryness under reduced pressure by Rota vapor and further concentrated by water bath at 40°C. Then, the gummy residue extract was packed in air tight brown glass bottles with proper label and kept in a refrigerator at 4°C until used for the experiment.

**Experimental induction of diabetes mellitus in rats**

Diabetes mellitus was induced in overnight fasted rats by a single intraperitoneal injection of freshly prepared solution of streptozotocin (60 mg/kg body weight) dissolved in 0.1 M citrate buffer, pH 4.5. The negative control rats were injected with the same volume of citrate buffer only. Streptozotocin injected rats were allowed to drink 5% glucose solution overnight to overcome initial drug induced hypoglycemic mortality.

Diabetes mellitus in streptozotocin injected rats was confirmed by measuring the fasting blood glucose concentration, 72 h after injection. The rats with fasting blood glucose level above 250 mg/dL were enrolled in the study. Treatment was started on the third day after streptozotocin injection and considered as zero day of treatment.

**Experimental design and treatment protocol**

Rats were divided as Group I: non-diabetic or normal control,
received appropriate volume of vehicle, that is, 1% tween 80, 10 ml/kg body weight; Group II: diabetic control, received the vehicle, that is, 1% tween 80, 10 ml/kg body weight; Group III: diabetic treatment, received 200 mg/kg body weight of ethanol extract of *A. remota* leaves; Group IV: diabetic treatment, received 400 mg/kg body weight ethanol extract of *A. remota* leaves; Group V: diabetic treatment, received 600 µg/kg body weight of glibenclamide. Ethanol extract of *A. remota* leaves and glibenclamide were administered every morning for 28 days by gastric intubation with an oral gavage.

**Measuring fasting blood glucose**

FBG was measured with SensoCard glucometer after the collection of blood sample from the tail vein of the overnight (12 to 15 h) fasted rats on days 0, 7, 14, 21 and 28.

**Determination of the weight of rats**

Body weight gain or lost in each experimental rat was measured and recorded on days 0, 7, 14, 21 and 28 with triple balance.

**Estimation of serum biochemical parameters**

At the end of the experimental period (on day 29th), all five groups of rats were sacrificed after overnight fast, by anesthetizing with diethyl ether, and then blood was collected by direct cardiac puncture. Serum was separated after coagulated at room temperature for 30 min and centrifuged at 3000 rpm for 10 min, which was stored at -20°C until biochemical parameters were determined. Total cholesterol, triacylglycerol, high density lipoprotein-cholesterol, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, urea and creatinine were determined with 902 automated chemistry analyzer. Low density lipoprotein-cholesterol level was calculated using Friedwald equation. Serum TP was determined with A 25 BioSystems chemistry analyzer.

**Statistical analysis**

All the values of body weight, fasting blood sugar and serum biochemical parameters were expressed as mean ± standard error of mean (SEM) and were performed using SPSS software package Version 20.0. The values were analyzed by one-way analysis of variance (ANOVA) followed by the Tukey’s post hoc test.

**RESULTS**

**Extraction**

In preparation of crude ethanol extract of *A. remota* from 600 g coarse powder leaves, 11.8% (70.80 g) yield of gummy residue was obtained.

**Effect of *A. remota* leaves extract on fasting blood glucose level in diabetic rats**

The effect of different doses of ethanol extract of *A. remota* on fasting blood glucose level in diabetic rats is
Table 1. Effect of A. remot a leaves extract on fasting blood glucose level in STZ induced diabetic rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Fasting blood glucose level (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 day</td>
</tr>
<tr>
<td>Normal control</td>
<td>97.2±5.2</td>
</tr>
<tr>
<td>Diabetic control</td>
<td>383.7±15.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + AREt (200 mg/kg)</td>
<td>386.5±16.0&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + AREt (400 mg/kg)</td>
<td>381.2±24.1&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + Glibenclamide (600 µg/kg)</td>
<td>393.0±12.8&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

The values indicate mean ±S.E.M (n=6).<sup>a</sup> p<0.05 compared with normal control values, <sup>b</sup> p<0.05 compared with diabetic control values and <sup>c</sup> p<0.05 compared with the initial level of fasting blood glucose level (0 day) of the rats in the respective group.

Table 2. Effect of A. remot a leaves extract on body weight of STZ induced diabetic rats.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Body weight (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0 day</td>
</tr>
<tr>
<td>Normal control</td>
<td>161.1±5.4</td>
</tr>
<tr>
<td>Diabetic control</td>
<td>142.6±3.4</td>
</tr>
<tr>
<td>Diabetic + AREt (200 mg/kg)</td>
<td>147.0±5.3</td>
</tr>
<tr>
<td>Diabetic + AREt (400 mg/kg)</td>
<td>150.2±6.9</td>
</tr>
<tr>
<td>Diabetic + Glibenclamide (600 µg/kg)</td>
<td>145.8±2.9</td>
</tr>
</tbody>
</table>

The values indicate mean ±S.E.M (n=6).<sup>a</sup> p<0.05 compared with normal control values, <sup>b</sup> p<0.05 compared with diabetic control group and <sup>c</sup> p<0.05 compared with the initial weight (0 day) of the rats in the respective group.

Table 3. Effect of A. remot a leaves extract on lipid profile of STZ induced diabetic rats after 28 days treatment.

<table>
<thead>
<tr>
<th>Groups</th>
<th>TC (mg/dL)</th>
<th>TG (mg/dL)</th>
<th>HDL-C (mg/dL)</th>
<th>LDL-C (mg/dL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal control</td>
<td>86.0±1.3</td>
<td>79.5±1.0</td>
<td>28.3±0.7</td>
<td>41.77±1.7</td>
</tr>
<tr>
<td>Diabetic control</td>
<td>191.2±6.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>163.50±3.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.8±0.7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>139.63±6.2&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + AREt (200 mg/kg)</td>
<td>129.5±2.1&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>95.67±3.7&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>25.2±0.4&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>85.20±2.3&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + AREt (400 mg/kg)</td>
<td>98.2±1.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>80.00±2.1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>29.77±0.5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>52.50±1.6&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Diabetic + Glibenclamide (600 µg/kg)</td>
<td>88.7±2.2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>69.67±2.9&lt;sup&gt;b&lt;/sup&gt;</td>
<td>35.5±0.9&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>39.23±2.5&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

The values indicate mean ±S.E.M (n=6).<sup>a</sup> p<0.05 compared with normal control values and <sup>b</sup> p<0.05 compared with diabetic control values.

given in Table 1. Fasting blood glucose level of diabetic control rats were significantly (p<0.05) higher than those of normal control rats on days 0, 7, 14, 21 and 28. Fasting blood glucose level significantly decreased in diabetic rats treated with 200 mg/kg and 400 mg/kg ethanol extract of A. remot a and 600 µg/kg glibenclamide on 21<sup>st</sup>, 14<sup>th</sup> and 7<sup>th</sup> day of treatment, respectively as compared with diabetic control rats.

Effect of A. remot a leaves extract on body weight in diabetic rats

As shown in Table 2, the body weights of untreated diabetic control rats were significantly reduced (p< 0.05) as compared to the normal control rats. Ethanol extract of A. remot a treated diabetic rats for 28 days significantly (p< 0.05) improved the body weight gain at 200 and 400 mg/kg body weight as compared to the diabetic control group, comparable to that of the standard at 600 µg/kg. The body weight of normal control rats significantly (p< 0.05) increased on days 7, 14, 21 and 28 as compared to the 0<sup>th</sup> day of treatment, while the diabetic control rats significantly decreased on days 14, 21 and 28 as compared to 0<sup>th</sup> day. However, the body weight of diabetic rats treated with any of the doses of ethanol extract of A. remot a did not significantly changed from the 0<sup>th</sup> day of treatment.

Effect of A. remot a leaves extract on serum lipid profile in diabetic rats

The level of serum lipid profile of experimental rats is shown in Table 3. Serum total cholesterol, triacylglycerol and low density lipoprotein-cholesterol increased...
Effect of *A. remota* leaves extract on serum alanine aminotransferase, aspartate amino transferase and alkaline phosphatase in diabetic rats

The serum levels of alanine aminotransferase, aspartate aminotransferase and alkaline aminotransferase significantly (p<0.05) increased in diabetic control rats as compared to normal controls. Administration of 200 mg/kg body weight and 400 mg/kg body weight ethanol extract of *A. remota* for 28 days significantly (p< 0.05) reduced the activity of alanine aminotransferase, aspartate amino transferase and alkaline phosphatase in diabetic rats as compared to diabetic control group. Similar effect was also observed with 600 µg/kg glibenclamide treatment (Table 4).

**DISCUSSION**

The present study was designed to investigate the
antihyperglycemic and antihyperlipidemic activities of ethanol extract of A. remota leaves in streptozotocin induced diabetic rats. Streptozotocin has been used to induce diabetes mellitus in experimental rats (Latha and Daisy 2011). A single intraperitoneal (IP) administration of 60 mg/kg streptozotocin effectively induced diabetes mellitus in rats, which was confirmed by elevated level of fasting blood glucose obtained from the tail of the rats after 72 h of injection.

The mechanism by which streptozotocin brings about diabetic mellitus includes selective destruction of insulin secreting pancreatic β-cells and minimize glucose uptake by peripheral tissues (Szkudelski, 2001). Ethanol extract of A. remota leaves reduced high fasting blood glucose level in streptozotocin induced diabetic rats. The mechanism antihyperglycemic of actions of ethanol extract of A. remota leaves might be due to an insulin mimetic effect on muscle and adipose tissues by either stimulating glucose uptake and metabolism (Daisy et al., 2010), by inhibiting hepatic gluconeogenesis (Cetto and Vázquez, 2010) and glycogenolysis (Rawi et al., 2011), by stimulation of regeneration process or increase pancreatic secretion of insulin from existing β-cells (Sharma et al., 2008) and/or inhibition activity against α-glucosidase enzymes in small intestine which convert disaccharides into monosaccharaides for sake of absorption (Shinde et al., 2008).

The difference in the magnitude of the effect on fasting blood glucose between 400 and 200 mg/kg ethanol extract of A. remota leaves doses might be attributed to the higher concentration of the active component(s) responsible for more fall of fasting blood glucose in the former than the later.

Fasting blood glucose lowering effect of ethanol extract of A. remota leaves is similar to Ajuga iva, which belongs in the same family (Hilaly and Lyoussei, 2002). Phytochemical investigations of A. remota have reported the presence of bioactive compounds such as iridoid and flavonol glycosides and phytoecdysteroids (Kubo et al., 1983 and Manguro et al., 2006). It has been suggested that antihyperglycemic effect of ethanol extract of A. remota leaves extract probably attributed to these constituents through improvement of insulin level (Sundaram et al., 2012).

The loss of body weight in untreated diabetic rats is due to increased muscle wasting and catabolism of others tissue proteins (Flatt et al., 1990). However, ethanol extract of A. remota leaves treatment improved the body weight in diabetic rats perhaps, due to the antihyperglycemic effect which was an indication of proper glucose utilization (Pari and Satheesh, 2004), its protective effect in muscle wasting and controlling protein turn over and/or improvement in diabetes mellitus associated disorders (Oyedemi et al., 2012).

Abnormalities in lipid profile are common complications in diabetes mellitus (Gibbons, 1986). Such abnormality represents the risk factors for coronary heart diseases. Activation of hormone sensitive lipase during insulin deficiency causes an increase in free fatty acid mobilization from adipose tissue and result in synthesis of triacylglycerol in liver (Mooradian, 2009). In addition, hyperglycemia is accompanied by a rise in total cholesterol, triacylglycerol, low density lipoprotein-cholesterol and a fall in high density lipoprotein-cholesterol (Gao et al., 2009). In the present study, total cholesterol, triacylglycerol and low density lipoprotein-cholesterol levels decreased and high density lipoprotein-cholesterol increased in ethanol extract of Ajuga remota leaves treated diabetic rats.

The remarkable control of high serum triacylglycerol in ethanol extract of A. remota leaves treated diabetic rats could be due to inhibition of endogenous triacylglycerol synthesis in liver (Xie et al., 2007) or improvement in insulin level or the presence of active component(s) in ethanol extract of A. remota leaves that suppressed the activity of hormone sensitive lipase in adipose tissue or increased activity of hepatic lipase or lipoprotein lipase accountable for the hydrolysis of excess lipoprotein bound triacylglycerol into fatty acids (Pritchard et al., 1986).

Increased level of HDL-C in ethanol extract of A. remota leaves treated groups could be due to the enhancement of lecithin: cholesterol acyltransferase (LCAT) which plays a key role in incorporating the free cholesterol into high density lipoprotein which take back to the liver (Senoucia et al., 2012). LDL-C reducing effect of ethanol extract of A. remota leaves presumably attributed to increased expression of low density lipoprotein receptor (LDLR), which enhance low density lipoprotein particles uptake in liver from the circulation, through the depletion of intracellular cholesterol (Bursill et al., 2007).

Serum TC lowering property of ethanol extract of A. remota leaves could be attributed to the availability of hypocholesterolemic compounds in ethanol extract of A. remota leaves that may act as inhibitor for hepatic hydroxyl methyl glutaryl CoA (HMG CoA) reductase in liver, which take part in cholesterol synthesis (Kumarappan et al., 2007) or increasing the fecal content by inhibiting the absorption of cholesterol from intestine (Raederstorff et al., 2003). Isolated phytoecdysteroids and iridoid glycosides, phytochemical constituent of ethanol extract of A. remota leaves, from other Ajuga species have shown antioxidant activity (Fan et al., 2011). Thus, reduction of total cholesterol in ethanol extract of A. remota leaves ethanol extract of A. remota leaves extract treated diabetic rats might also attributed to the aforementioned phytochemical constituents by reducing lipid peroxidation by scavenging free radicals (Sharma et al., 2008).

The decrease in total cholesterol, triacylglycerol and low density lipoprotein-cholesterol and an increase in high density lipoprotein-cholesterol after 28 days treatment showed a dose dependent trend, indicating that
efficacy was proportional to the dose of ethanol extract of *Ajuga remota* leaves. Similar hypocholesterolemia and hypotriacylglycerol effects were observed by A. *iva* whole plant extract in streptozotocin induced diabetic rats (Hilaly et al., 2007).

The activity of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase in serum are generally indicators of liver function. In diabetic rats, the level of these enzymes are elevated due to necrosis of liver cells by the injection of STZ (Hwang et al., 1996). However, ethanol extract of *A. remota* leaves treated diabetic rats showed decreased in the activity of serum alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase enzymes that might support its hepatoprotective effect and normalization capability of impaired liver metabolism in diabetic rats.

There is increased protein catabolism with the flow of amino acids into the liver, which feeds gluconeogenesis as a result of insulin deficiency during uncontrolled diabetes mellitus. This might account for the decrease in serum total protein content in STZ induced diabetic control rats (Narendhirakannan et al., 2006). The results of the present study demonstrated that treatment of diabetic rats with ethanol extract of *A. remota* leaves caused a significant increase in serum total protein which might be attributed to an improvement in glycemic control and insulin secretion that increase protein synthesis or decrease protein degradation (Gao et al., 2009).

Negative nitrogen balance is manifested in diabetic rats associated with enhanced proteolysis in muscle and other tissues. Impaired balance of nitrogen coupled with lowered protein synthesis leads to increased concentrations of urea and creatinine in serum (Basha and Subramanian, 2011) indicating progressive renal damage in diabetic rats (Anjaneyulu and Chopra, 2004). Treatment with ethanol extract of *A. remota* leaves resulted in a considerable reduction to near normal in serum urea and creatinine level indicating the renoprotective role of ethanol extract of *A. remota* leaves or delay diabetic nephropathy development.

Hepatoprotective and renoprotective effect of ethanol extract of *A. remota* leaves might be due to phytoecdysteroids, possibly through their antioxidant activity (Krishnan et al., 2007). In conclusion, these findings demonstrated that ethanol extract of *A. remota* leaves possesses antihyperglycemic and antihyperlipidemic properties which might support the traditional claim of its use in diabetes.

**Conflict of Interests**

The authors have not declared any conflict of interests.

**ACKNOWLEDGEMENT**

The authors thank Addis Ababa University for providing fund for the research.

**REFERENCES**


Assefa et al.          23
Oxidative Stress Damage in an HAI, Panganamala diabetic rats -
diabetic in Goto-Bursill CA, Abbey M, Roach PD
Mooradian AD (2009).
Gibbons GF
Oyedemi S, Bradley G, Afolayan A
Pari L, Satheesh MA
Flatt SKS, Day C, Bailey CJ, Flat PR
Sundaram R, Naresh R, Ranadevan R, Shanthi P, Sachdanandam P
Manguro LOA, Wagai
Full Length Research Paper

Determination of bioactive constituents of *Rauwolfia vomitoria* Afzel (Asofeyeje) roots using gas chromatography-mass spectrometry (GC-MS) and Fourier transform infrared spectrometry (FT-IR)

Okereke, S. C.¹*, Ijeh, I. I.² and Arunsi, U. O.¹

¹Department of Biochemistry, Abia State University, Uturu, Nigeria.
²Department of Biochemistry, Michael Okpara University, Umudike, Nigeria.

Received 27 November, 2016; Accepted 28 December, 2016

*Rauwolfia vomitoria* Afzel belong to the family of Apocynacea with a common name serpent wood and Igbo name as akanta. It is used traditionally to treat hypertension and rheumatoid arthritis. The present study deals with GC-MS determination and FT-IR analysis of methanolic root extract of the named plant. Exactly thirty phytochemical constituents have been identified by comparing the chromatogram peek values of unknown compounds with entries in NIST database. The major bioactive compounds were 2-Formyl-9-[β-d-ribofuranosyl]hypoxanthine (8.63%), 5-Cyclopropylcarbonyloxypenta-decane (5.58%), 1,2,5-Oxadiazol-3-carboxamide-4,4'-azobis-2,2'-dioxide (4.47%), 1-(5-Bicyclo[2.2.1]heptyl)ethylamine (3.66%), 1-Adamantanemethylamine,α-methyl- (2.22%), Diphenylephrine (1.26%), Imidazole,2-amino-5-[[2-carboxyvinyl]- (0.85%), Spiro[androst-5-ene-17,1'-Cyclobutan]-2'-one,3-hydroxy-,(3β,17β)- (0.82, and Cyclohexan-1,4,5-triol-3-one-1-carboxylic acid (0.65%). The FTIR spectrum confirmed the presence of alkyl halides, alcohols, phenols, secondary alcohols, tertiary alcohols, aromatic ethers, aldehydes, ketones, aliphatic nitro compound, aromatic organophosphorus compounds, aromatic compounds, carboxylic acid derivatives, alkenes, saturated ketones, and alkanes. Hence, this study offers bases of employing *R. vomitoria* as herbal alternative for the treatment of various diseases.

**Key words:** Fourier transform infrared spectrometry (FTIR), gas chromatography-mass spectrometry (GC-MS), phytochemical, *Rauwolfia vomitoria* Afzel.

INTRODUCTION

Developing countries most especially the rural areas are constantly being inundated by infectious diseases and attempts to manage these ailments with conventional drugs have posed mankind with a lot of health consequences. Researches over the years have shown that over dependence on drugs as sole remedies for treating diseases have led to malfunction of important organs of the body such as the liver, the kidney, eyes,
lungs and the brain. Sequel to this, attentions are now being shifted to the use of medicinal plants in the treatment of infectious diseases. The economic realities of the developing countries, where most people hardly can afford good meal, housing, clothing and the expensive pharmaceutical products for health-care, has forced many to resort to alternative complementary medicine. Again, the development of drug-resistant strains of microorganisms and autoimmune problems make it imperative for a continued search for new drugs from natural products (Vaitheswarn and Edward, 2014). Cowan (1999) reported that plants still represent large untapped sources of structurally novel compounds that might serve as lead for the development of novel drugs. Traditional systems of medicines are prepared from a single plant or combinations of number of plants. The efficacy depends on the use of proper plant part and its biological potency which in turn depends upon the presence of required quantity and nature of secondary metabolite in a raw drug (Savithramma et al., 2010; Vinoth et al., 2011). Herbal medicines are safer than synthetic medicines because the phytochemicals in the plant extract target the biochemical pathway. These bioactive compounds that contribute to the pharmacological efficacy of medicinal plants have recently been identified with relatively expensive and often laborious techniques such as gas chromatography (GC) combined with specific detections schemes (Eisenhauer et al., 2009). The specific detection schemes could be mass spectrometry (MS) or Fourier transform infrared spectrometry (FTIR). Gas chromatography combined with mass spectroscopy (GC-MS) can identify pure compounds present at less than 1 ng biological specimen and quantification purpose (Liebler et al., 1996). The unknown organic compounds in a complex mixture can be determined by interpretation and also by matching the spectra with reference spectra (Hites, 1997). FT-IR spectroscopy has demonstrated to be a reliable and sensitive method for finding out the functional groups present in plant samples using IR region in the range of 400 to 4000 cm⁻¹. For most common plant compounds, the spectrum of an unknown compound can be identified by comparison to a library of known compounds (Griffiths and Haseth, 1986).

Nigeria is rich in diverse plant resources, therefore screening for active compounds residents in plants with effective protection and treatment of different diseases and infections should be pursued. Rauwolfia vomitoria belongs to the family Apocynaceae and its common names include serpent wood, poison’s devil pepper and swizzler stick. The plant is a shrub or tree which grows over 10 m tall of the forest and common in secondary growth throughout most of African regions. Sometimes due to the flower and the sweet scented fruits and it is sometime planted as an ornamental shrub. In Nigerian local languages, R. vomitoria is called asofeyeje (Yoruba), akanta (Igbo), wada (Hausa), mmoneba (Efik) and utoenyin (Ibibio) (Mecha et al., 1980; Ekutudo, 2003; Ehiagbonare, 2004). The plant is of different species: the Indian species (Rauvolfia serpentina) and the African species (R. vomitoria) (Kutalek and Prinz, 2007). The roots, root bark, leaves and stem-bark are employed in herbal medicine for the treatment of several ailments. Kutalek and Prinz (2007) reported that the plant is used in ethnomedicine against snake bites, fever and nervous disorders. They further reported that a watery solution of the bark of R. vomitoria can be used against such parasites as lice and scabies. R. vomitoria is employed in the treatment of rheumatoid arthritis (Fapojuwomi and Asinwa, 2013). Sharma (2004) added that the root of R. vomitoria is good for the treatment of snake bites, insect stings, nervous disorders, mania, epilepsy, intractable skin disorders such as psoriasis, excessive sweating, itching, hypertension, sedative, uterine contraction in child birth and gynecological ointment for the treatment of menopausal disorders. Prajapati et al. (2007) observed that R. vomitoria is a sedative, hypnotic, good for reducing blood pressure, good for treating insanity, antihelminthic, an antidote to snake venom, anti-anxiety agent and stimulant to central nervous system. A decoction of the root of the plant could be given during labour pains to increase uterine contraction. Odugbemi (2008) also reported that R. vomitoria (Asofeyeje) is good for the treatment of hypertension, insomnia, nervous disorder, jaundice, fever, diarrhea, dysentery, scabies, mental disorders, antihelmintics and malaria.

Reserpin is an alkaloid derived from R. vomitoria and is the major reason for the medicinal use of the plant in India. Reserpin is derived from the root bark of the plant and was isolated in 1952 as purified alkaloid for the treatment of hypertension. Reserpin irreversibly binds to the storage vesicles of neurotransmitters, particularly norepinephrine, serotonin and dopamine. Eventually, catecholamine depletion occurs because of the body’s inability to store these neurotransmitters. Therefore, the study employed gas chromatography combined with mass spectrophotometry and Fourier transform infrared (GC-MS/FT-IR) technique to determine the phytochemicals present and the functional groups they possess, respectively.

MATERIALS AND METHODS

Collection and identification of plant

R. vomitoria roots were collected from a bush near Abia State University. The collected specimen was taken to the Forest Herbarium, Ibadan (FHI), Nigeria for proper identification. The specimen already was existing in the FHI. It has the serial No. 72.

Preparation of extract for GC-MS

The roots of R. vomitoria were washed to remove sand and humus, and then allowed to dry under shade. The roots were first chopped into small particles and ground to powder using a grinder. Five
grams of the plant powder was transferred to a round bottom flask and treated with methanol in a soxhlet apparatus. The temperature was maintained between 45 and 47°C and lasted for 24 h. The extract was collected and evaporated using vacuum distillation unit. The methanolic extract so obtained was then subjected to GC-MS.

FT-IR spectroscopic analysis

The FT-IR spectra of the samples were determined using a Fourier transform infrared spectrometer (Thermo Scientific Nicolet iS5) IDI Transmission Accessory. Approximately, 2 mg of the solid sample of *R. vomitoria* was ground with 200 mg of dried potassium bromide (KBr) to form a homogenous powder, which was compressed into a thin pellet by using 15Tons hydraulic press. KBr pellet holder was then recorded for FT-IR measurement in the wave number range from 4000 to 400 cm⁻¹ using 16 scan.

GC-MS analysis

GC-MS analysis on the methanolic extract was carried out using Agilent 7890A-5975C GC-MS system, employing the following conditions. HPS-Column (30×0.25 μm), operating in electron impact mode at 70 eV; carrier gas flow (a constant) = 1 ml/min. Injection volume was set at 0.5 μL, at split ratio of 10:1. The injection temperature was 250°C and ion source temperature 280°C. Oven temperature for 2 min at the initial 70°C and to 280°C at 15°C/min rate for 5 min. The mass spectra was measured at 70 eV.

Identification of components

Interpretation of mass spectrum obtained from GC-MS was conducted using the database of National Institute Standard and Technology (NIST) having more than 82,000 patterns. The spectrum of the unknown component was compared with the spectra of the known components stored in the NIST library. The name, molecular weight, molecular formula and structure of the components of the test materials were ascertained.

Identification of functional groups

The FTIR spectrum was used to identify the functional groups of the active components present in plant sample based on the peaks values in the region of IR radiation. When the plant extract was passed into FTIR, the functional groups of the components were separated based on its peaks ratio.

RESULTS

The results of GC-MS/FT-IR and biological activities of identified compounds of methanol extract of roots of *R. vomitoria* are presented in Figures 1 and 2 and Tables 1 to 3. A total of thirty compounds were identified from the methanol root extract of *R. vomitoria*. The identification of the phytochemical compounds was confirmed based on the peak area, retention time and molecular formula (Figure 1 and Table 1). According to Duke’s phytochemical and ethnobotanical databases (1998), the biological activities of some of the identified compounds are presented in Table 2. The results of FT-IR spectroscopic analysis revealed the presence of certain
DISCUSSION

The techniques of GC-MS/FT-IR have proved effective and more reliable in the determination of chemical compounds present in plants. Earlier reports elucidated the biological activities of Cyclohexan-1,4,5-triol-3-one-1-carboxylic acid, Spiro[androst-5-ene-17,1'-Cyclobutan]-2'-one,3-hydroxy-,(3β,17β), 2-Trifluoroacetoxydodecane and Adamantane methylamine,α-methyl-. Jeyadevi et al. (2013) reported that cyclohexan-1,4,5-triol-3-one-1-carboxylic acid has antibacterial activity against Escherichia coli, Srinivasan et al. (2014) observed that imidazole,2-amino-5-{[2-carboxylvinyl]} has antimicrobial activities, spiro[androst-5-ene-17,1'-Cyclobutan]-2'-one,3-hydroxy-,(3β,17β) possesses anti-inflammatory and antimicrobial activities; Mohan et al. (2014) reported that 2-Trifluoroacetoxydodecane, a fluorocompound has antimicrobial, anticancer and anti-inflammatory, while Xing et al. (2008) observed that 1-Adamantanemethylamine,α-methyl- otherwise known as Rimantadine, inhibits in vitro replication of influenza A virus isolates from each of the three antigenic sub-types (H1N1, H2N2 and H3N3) that have been found in man. From the result of the functional group analysis, it can be inferred that alkyl halides, alcohols, phenols, secondary alcohols, tertiary alcohols, aromatic ethers, aldehydes, ketones, aliphatic nitro compound, aromatic organophosphorus compounds, aromatic compounds, carboxylic acid derivatives, alkenes, saturated ketones and alkanes might be responsible for the various medicinal properties of the root of R. vomitoria.

Conclusion

In the present study, the FTIR and GC-MS spectral
Table 1. List of compounds identified at various retention times from methanolic extract of roots of *Rauwolfia vomitoria* by GC-MS.

<table>
<thead>
<tr>
<th>S/N</th>
<th>RT</th>
<th>Compound name</th>
<th>MW</th>
<th>Formula</th>
<th>Area (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.344</td>
<td>Cyclopropyl carbinol</td>
<td>72</td>
<td>C₈H₁₂O</td>
<td>0.28</td>
</tr>
<tr>
<td>2</td>
<td>3.467</td>
<td>1-pentanol, 4-amino</td>
<td>103</td>
<td>C₃H₁₇NO</td>
<td>1.19</td>
</tr>
<tr>
<td>3</td>
<td>3.954</td>
<td>Cyclohexan-1, 4, 5-triol-3-one-1-carboxylic acid</td>
<td>190</td>
<td>C₁₇H₂₀O₅</td>
<td>0.65</td>
</tr>
<tr>
<td>4</td>
<td>4.932</td>
<td>Diphenylephrine</td>
<td>167</td>
<td>C₉H₁₂NO₂</td>
<td>1.26</td>
</tr>
<tr>
<td>5</td>
<td>5.216</td>
<td>Phenol, 2, 6-dimethoxy-</td>
<td>154</td>
<td>C₈H₁₀O₃</td>
<td>1.58</td>
</tr>
<tr>
<td>6</td>
<td>5.387</td>
<td>2-Trifluoroacetoxydodecane</td>
<td>282</td>
<td>C₁₈H₂₅F₃O₂</td>
<td>1.84</td>
</tr>
<tr>
<td>7</td>
<td>5.654</td>
<td>1-(5-Bicyclo[2.2.1]heptyl)ethylamine</td>
<td>139</td>
<td>C₉H₁₇N</td>
<td>3.66</td>
</tr>
<tr>
<td>8</td>
<td>6.066</td>
<td>2-Formyl-9-[β-d-ribofuranosyl]hypoxanthine</td>
<td>296</td>
<td>C₁₇H₂₅N₂O₅</td>
<td>8.63</td>
</tr>
<tr>
<td>9</td>
<td>6.248</td>
<td>1-Guanidinosuccinimide</td>
<td>141</td>
<td>C₆H₁₄N₂O₂</td>
<td>0.31</td>
</tr>
<tr>
<td>10</td>
<td>6.398</td>
<td>3-Nonyn-2-ol</td>
<td>140</td>
<td>C₉H₁₆O</td>
<td>0.62</td>
</tr>
<tr>
<td>11</td>
<td>6.451</td>
<td>Imidazole, 2-amino-5-[2-carboxy]vinyl-</td>
<td>153</td>
<td>C₆H₁₆N₂O₂</td>
<td>0.85</td>
</tr>
<tr>
<td>12</td>
<td>6.874</td>
<td>Cyclohexanemethanol, 4-ethenyl-α, α, 4-trimethyl-3-(1-methylethenyl) -[1R-(1α, 3α, 4β)]-</td>
<td>222</td>
<td>C₁₅H₂₈O</td>
<td>0.31</td>
</tr>
<tr>
<td>13</td>
<td>6.949</td>
<td>2-Propenoic acid, 1-methylindecylester</td>
<td>240</td>
<td>C₁₅H₂₈O₂</td>
<td>1.97</td>
</tr>
<tr>
<td>14</td>
<td>7.302</td>
<td>3-&lt;Prop-2-enolylkoxy)dodecane</td>
<td>240</td>
<td>C₁₅H₂₈O₂</td>
<td>2.97</td>
</tr>
<tr>
<td>15</td>
<td>7.457</td>
<td>5-Cyclopropylcarboxyloxypenta-decane</td>
<td>296</td>
<td>C₁₅H₂₆O₂</td>
<td>5.58</td>
</tr>
<tr>
<td>16</td>
<td>8.002</td>
<td>4-((1E)-3-Hydroxy-1-Propenyl)-2-methoxyphenol</td>
<td>180</td>
<td>C₁₀H₁₂O₃</td>
<td>0.47</td>
</tr>
<tr>
<td>17</td>
<td>8.297</td>
<td>Didodecylphthalate</td>
<td>502</td>
<td>C₂₂H₄₂O₄</td>
<td>5.14</td>
</tr>
<tr>
<td>18</td>
<td>9.142</td>
<td>Cyclopentaneundecanoic acid, methyl ester</td>
<td>268</td>
<td>C₁₇H₂₂O₂</td>
<td>2.38</td>
</tr>
<tr>
<td>19</td>
<td>9.243</td>
<td>Undecanoic acid</td>
<td>186</td>
<td>C₁₁H₁₄O₂</td>
<td>0.26</td>
</tr>
<tr>
<td>20</td>
<td>9.564</td>
<td>Propanamide, 3, (3,4-dimethylphenylephrine)</td>
<td>241</td>
<td>C₁₁H₁₅N₂O₃S</td>
<td>1.98</td>
</tr>
<tr>
<td>21</td>
<td>10.019</td>
<td>9,12-Octadecadienal</td>
<td>264</td>
<td>C₁₈H₃₂O</td>
<td>1.73</td>
</tr>
<tr>
<td>22</td>
<td>10.147</td>
<td>2-Decyn-1-ol</td>
<td>154</td>
<td>C₁₀H₁₄O</td>
<td>0.48</td>
</tr>
<tr>
<td>23</td>
<td>10.843</td>
<td>3-Decyn-2-ol</td>
<td>154</td>
<td>C₁₀H₁₄O</td>
<td>0.60</td>
</tr>
<tr>
<td>24</td>
<td>10.917</td>
<td>1-methyldecylamine</td>
<td>199</td>
<td>C₁₂H₂₈N</td>
<td>1.33</td>
</tr>
<tr>
<td>25</td>
<td>13.019</td>
<td>Urs-12-en-28-ol</td>
<td>426</td>
<td>C₃₀H₅₀O</td>
<td>0.28</td>
</tr>
<tr>
<td>26</td>
<td>13.822</td>
<td>2, 6, 10-Dodecatrien-1-ol, 3, 7, 11-trimethyl-</td>
<td>222</td>
<td>C₁₅H₂₈O</td>
<td>1.25</td>
</tr>
<tr>
<td>27</td>
<td>13.929</td>
<td>3-Hydroxyquininalbarbitone</td>
<td>254</td>
<td>C₁₄H₁₈N₂O₄</td>
<td>0.56</td>
</tr>
<tr>
<td>28</td>
<td>14.234</td>
<td>1, 2, 5-Oxadiazol-3-carboxamide-4, 4'-azobis-2, 2'-dioxide</td>
<td>284</td>
<td>C₆H₁₄N₆O</td>
<td>4.47</td>
</tr>
<tr>
<td>29</td>
<td>14.522</td>
<td>1-Adamantanemethamine, α, α-methyl-</td>
<td>179</td>
<td>C₁₂H₂₁N</td>
<td>2.22</td>
</tr>
<tr>
<td>30</td>
<td>14.581</td>
<td>Spiro[androst-5-ene-17, 1'-Cyclobutan]-2'-one, 3-hydroxy-, (3β, 17β)-</td>
<td>328</td>
<td>C₂₀H₃₂O₂</td>
<td>0.82</td>
</tr>
</tbody>
</table>

Analysis of *R. vomitoria* root extract composed of various functional groups and variety of bioactive compounds which are responsible for many biological activities. In addition, further research is necessary to identify and purify the active compounds responsible for therapeutic activity.
Table 2. Biological activities of phytochemical compounds identified in methanol extract of roots of *Rauwolfia vomitoria*.

<table>
<thead>
<tr>
<th>S/N</th>
<th>Compound name</th>
<th>Biological activity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1-pentanol,4-amino</td>
<td>Increase aromatic amino acid decarboxylase activity</td>
</tr>
<tr>
<td>2</td>
<td>Cyclohexan-1,4,5-triol-3-one-1-carboxylic acid</td>
<td>Acidifier, inhibit production of uric acid, urinary acidulant</td>
</tr>
<tr>
<td>3</td>
<td>3-Nonyl-2-ol</td>
<td>Oligosaccharide provider</td>
</tr>
<tr>
<td>4</td>
<td>2-Propenoic acid, 1-methylindecyclester</td>
<td>Arachidonic acid inhibitor, Increase aromatic amino acid decarboxylase activity, inhibit production of uric acid, urinary acidulant</td>
</tr>
<tr>
<td>5</td>
<td>3-(Prop-2-enoyloxy)dodecane</td>
<td>Proteic activity</td>
</tr>
<tr>
<td>6</td>
<td>4-((1E)-3-Hydroxy-1-Propenyl)-2-methoxyphenol</td>
<td>Anticancer, antidote (emetine), cytochrome-P4502E1 inhibitor, EDRF promoter, elastase inhibitor, endothelium-derived relaxing factor promoter, enteromotility enhancer, ethanol-absorption inhibitor, fertility enhancer, enteroparasiticide, memory enhancer,</td>
</tr>
<tr>
<td>7</td>
<td>Cyclopentaneundecanoic acid, methyl ester</td>
<td>Increase aromatic amino acid decarboxylase activity, inhibit production uric acid, arachidonic acid inhibitor</td>
</tr>
<tr>
<td>8</td>
<td>Undecanoic acid</td>
<td>Acidifier, inhibit production of uric acid, urinary acidulant</td>
</tr>
<tr>
<td>9</td>
<td>2-Decyn-1-ol</td>
<td>Oligosaccharide provider</td>
</tr>
<tr>
<td>10</td>
<td>3-Decyn-2-ol</td>
<td>Oligosaccharide provider</td>
</tr>
<tr>
<td>11</td>
<td>Urs-12-en-28-ol</td>
<td>Oligosaccharide provider, decrease endothelial leukocyte-adhesion, energizer, fertility enhancer, stimulate PUFAs desaturases and elongase enzymes, trypsin enhancer</td>
</tr>
<tr>
<td>12</td>
<td>2, 6,10-Dodecatrien-1-ol,3,7,11-trimethyl-</td>
<td>Oligosaccharide provider</td>
</tr>
<tr>
<td>13</td>
<td>1-Adamantanemethylamine,α-methyl-</td>
<td>Catechol-O-methyl-transferase inhibitor, methyl donor, methyl-hyaloidine inhibitor</td>
</tr>
<tr>
<td>14</td>
<td>Spiro[androst-5-ene-17,1'-Cyclobutan]-2'-one,3-hydroxy-,(3β,17β)]-</td>
<td>-</td>
</tr>
</tbody>
</table>

Duke’s phytochemical and ethnobotanical databases

Table 3. FTIR analysis of methanolic extract of roots of *Rauwolfia vomitoria*.

<table>
<thead>
<tr>
<th>S/N</th>
<th>Wave number (cm⁻¹)</th>
<th>Functional group</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>558.27</td>
<td>C-X (Bromoalkanes, alkyl halides)</td>
</tr>
<tr>
<td>2</td>
<td>661.80</td>
<td>O-H (Alcohols and phenols)</td>
</tr>
<tr>
<td>3</td>
<td>897.97</td>
<td>=C-H and =CH₂ out of plane bending (alkenes)</td>
</tr>
<tr>
<td>4</td>
<td>1029.02</td>
<td>C-X (Fluoroalkanes, alkyl halides)</td>
</tr>
<tr>
<td>5</td>
<td>1105.72</td>
<td>C-O (Secondary alcohols)</td>
</tr>
<tr>
<td>6</td>
<td>1155.99</td>
<td>C-O (Tertiary alcohols)</td>
</tr>
<tr>
<td>7</td>
<td>1236.47</td>
<td>C-O (Aromatic ethers)</td>
</tr>
<tr>
<td>8</td>
<td>1321.59</td>
<td>A-CH₃ bending (Aldehydes and ketones)</td>
</tr>
<tr>
<td>9</td>
<td>1370.30</td>
<td>N-O (Aliphatic nitro compounds)</td>
</tr>
<tr>
<td>10</td>
<td>1422.55</td>
<td>O-H bending in plane (Alcohols and phenols)</td>
</tr>
</tbody>
</table>
### Table 3. Contd.

<table>
<thead>
<tr>
<th></th>
<th>1458.43</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>P-C (Aromatic organophosphorus compounds)</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>1504.67</td>
<td>C=C (aromatic compounds)</td>
</tr>
<tr>
<td>13</td>
<td>1593.90</td>
<td>C=O (carboxylic acids/derivatives)</td>
</tr>
<tr>
<td>14</td>
<td>1636.36</td>
<td>C=C (alkenes)</td>
</tr>
<tr>
<td>15</td>
<td>1731.98</td>
<td>C=O (saturated ketones)</td>
</tr>
<tr>
<td>16</td>
<td>2897.74</td>
<td>CH₃, CH₂, and CH band (Alkanes)</td>
</tr>
<tr>
<td>17</td>
<td>3333.26</td>
<td>O-H (strong bond) (Alcohols and phenols)</td>
</tr>
</tbody>
</table>

### Conflicts of Interests

The authors have not declared any conflict of interests.

### REFERENCES


Screening of some pyrazole derivatives as promising antileishmanial agent

Abdu Tuha¹, Adnan A. Bekhit²,³ and Yimer Seid¹*

¹Department of Pharmacy, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. ²Department of Pharmaceutical Chemistry, School of Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia. ³Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.

Received 30 June, 2015; Accepted 2 August, 2015

Pyrazole derivatives (I-VII) were prepared in good yields using aldol condensation followed by cyclization and were characterized by elemental analysis, IR and ¹H NMR spectroscopy. In vitro antileishmanial activity test was conducted using Alamar blue reduction method. The test revealed that the synthesized compounds (except compound IIb) exhibit better antileishmanial activity than the standard drug miltefosine and lower antileishmanial activity (except compounds III and IIIb) compared to the standard drug amphotericin B deoxycholate. Compound IIIb, phenyl pyrazoline with propanoyl side chain, 1-(3-phenyl-5-(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)-4,5-dihydropyrazol-1-yl)propan-1-one, was found to be the most active (IC₅₀= 0.0112 µgml⁻¹) than the standards miltefosine (IC₅₀ = 0.3±0.04 µgml⁻¹) and amphotericin B deoxycholate (IC₅₀ = 0.2±0.02 µgml⁻¹) for Leishmania donovani. Compound III was found to be the most active (IC₅₀ = 0.28±0.03 µgml⁻¹) and has comparable antileishmanial activity to the standard miltefosine (IC₅₀ = 0.3±0.04 µgml⁻¹) and amphotericin B deoxycholate (IC₅₀ = 0.2±0.02 µgml⁻¹) on Leishmania aethiopica amastigote.

Key words: Pyrazole derivative, biological screening, antileishmanial agent.

INTRODUCTION

Leishmaniasis is a group of vector-borne diseases caused by species of the genus Leishmania, a compulsory intra-cellular parasite of the mammalian host cell (dos Santos et al., 2011; Luiz et al., 2012). Leishmania parasites exist in two forms: amastigote in the mammalian host and a flagellated promastigote in the insect vector (dos Santos et al., 2011). Clinical manifestation of leishmaniasis occur in four major forms in humans: (i) visceral, the most severe and life-threatening form; (ii) cutaneous, originating as nodules and ulcers that may persist for years; (iii) diffuse cutaneous leishmaniasis, which is a long-lasting disease due to a deficient cellular-mediated immune response; and (iv) mucocutaneous, causing permanent lesions in the mouth, nose or genital mucosa (dos et al., 2011; Luiz et al., 2012; Sánchez-Moreno et al., 2012). This life-threatening disease that affects about 12 million people worldwide with 1.5 million to 2 million new cases of cutaneous leishmaniasis (CL) and 500,000 new cases of visceral leishmaniasis (VL) each year is endemic in the tropical and sub-tropical regions (Desjeux,
Endemic human leishmaniasis is reported in 88 countries, majority of them are low-income countries (Desjeux, 1999). East Africa is one of the world’s main endemic areas for VL, and over the last 20 years has gained dramatic increase in the number of VL cases, due to a complexity of factors (Reithinger et al., 2007). Several studies have convincingly shown that malnutrition, HIV and genetic susceptibility are individually responsible for VL (Bucheton et al., 2002). The epidemiological pattern of *Leishmania* species is changing, with a tendency to urbanization and geographic expansion. Despite the high worldwide prevalence, no vaccine for Leishmaniasis and complex vector control, few advances were made in the treatment of this disease (dos et al., 2011; Marra et al., 2012).

The difficulty to control this parasitic disease remains a serious problem mainly due to the diversity of mammalian reservoirs (wild and domestic animals), species of vectors and *Leishmania* species (dos et al., 2011). Chemotherapy for leishmaniasis is generally ineffective mainly due to the emergence of drug-resistant strains and toxicity of the therapeutic agents (Marra et al., 2012). The pentavalent antimonials compounds, such as sodium stibogluconate (pentostan) and meglumine antimoniate (glucantime) are widely used as primary therapy. Its failure in some cases to treat visceral leishmaniasis in Africa (dos et al., 2011; Sundar et al., 2007) the pentavalent antimonials compounds, such as sodium stibogluconate (pentostan) and meglumine antimoniate (glucantime) are widely used as primary therapy, but they induce toxic side effects together with drug resistance (dos et al., 2011; Braga et al., 2007).

Amphotericin (AmBisome) is now the treatment of choice. Its failure in some cases to treat visceral leishmaniasis (*Leishmania donovani*) has been reported in Sundar (Sundar et al., 2007); but this may be related to host factors such as co-infection with HIV or tuberculosis rather than parasite resistance. Mitelofosine (Impavido) is a new drug for visceral and cutaneous leishmaniasis. Paromomycin drug is thought to be an inexpensive and effective treatment for leishmaniasis (Mueller et al., 2007).

Pyrazole derivatives were found to possess various important biological activities, such as antibacterial (Samir et al., 2011; Nilesh and Manish, 2011), anti-inflammatory (Adnan et al., 2008; Lingaiah et al., 2011), antioxidant (Ramesh and Chetan, 2011) ACE inhibitory (Marco et al., 2010), anti-cancer (Hai-Jun et al., 2010), MAO-B inhibitory (Nesrin et al., 2007), antidepressant (Mohamed et al., 2009), antiviral (Guiping et al., 2008), antimycobacterial (Ramaiyan et al., 2010; Daniele et al., 2008), antileishmanial (Bernardino et al., 2006; Naresh et al., 2006), and antimalarial (Katlyar et al., 2005; Cunico et al., 2006) activities.

These reports have been useful for biologist, chemists and pharmacists engaged in the development of new drugs and/or synthetic routes from pyrazoline derivatives. Pyrazoline derivatives were reported to possess significant in vitro anti-leishmanial activity (Bekhit et al., 2014). This has prompted the synthesis and investigation of safe, effective and cheap antileishmanial agent from pyrazoline derivatives containing phenyl or thiophenyl moiety in this research laboratory.

**METHODOLOGY**

¹H NMR spectra were recorded in Bruker Avance DMX400 FT-NMR spectrometer and IR spectra using Shimadzu 8400SP Spectrophotometer. For melting point and elemental analysis, Eelectro thermal IA9100 hot storage melting point apparatus and Perkin Elmer 2400 elemental analyzer were respectively used. Haemocytometer was used for counting leishmania parasites. Purity of the reaction products were checked by means of thin layer chromatography (TLC) using silica gel plate with fluorescent indicator, melting points, IR and ¹H NMR spectra.

**Chemicals and reagents**

Acetophenone, 2-acetyltithiophene and hydrazine hydrate (Sigma Aldrich), ethanol, glacial acetic acid, propanoic acid, hydrochloric acid, KOH, absolute methanol, acetonitrile, chloroform, ethyl acetate, benzene, sodium citrate, distilled H₂O, dimethyl sulfoxide (BDH, England), alamar blue, RPMI 1640 were used throughout the experiments.

**Parasite strain**

*L. donovani*, a leishmanial parasite that causes visceral leishmaniasis in Africa and *L. aethiopica* the leading cause of cutaneous leishmaniasis in Ethiopia were used for the antileishmanial testing.

**Standard drugs**

Amphotericin B deoxycholate (Fungizone®, R. E Squibb, UK) and miltefosine/hexadecylphosphocholine (A G Scientific, San Diego, CA, USA) were used as standard drugs in the determination of the antileishmanial activity of the synthesized compounds.

**Synthesis of target compounds**

The intermediate α, β unsaturated ketones (II and III) were synthesized by aldol condensation of 1-phenyl-3-p-tolyl-1H-pyrazole-4-carbaldehyde I with 2-acetyltithiophene and acetonophenone in alcoholic KOH. The target thienyl and phenyl pyrazolines (Figures 1 and 2) were synthesized by cyclization of the intermediate α, β unsaturated ketones (II and III) with hydrazine hydrate in ethanol or the appropriate aliphatic acid (Tuha et al., 2014)

**Culture conditions**

*L. donovani* and *L. aethiopica* were cultured in tissue flasks containing RPMI 1640 medium supplemented with 10% HIFCS and 100 IU penicillin and 100 µg/ml streptomycin solution at 26°C (Tariku et al., 2010; Habtemariam, 2003; Seifert et al., 2010).

**Stock solution and working concentration preparation**

All the compounds tested (II, IIa, IIIa, IIIb, IIIc, IIlc) were dissolved in DMSO to a final concentration of 1 mg/ml. Both test and standard solutions were serially diluted to appropriate
Figure 1. Scheme of synthesis of intermediate α, β unsaturated ketone (II) and thienyl pyrazoline derivatives.

Figure 2. Scheme of synthesis of intermediate α, β unsaturated ketone (III) and phenyl pyrazoline derivative.
concentrations using complete media. The test compounds were prepared by three fold serial dilutions from 10 µg ml⁻¹ to 0.04 µg ml⁻¹. Amphotericin B deoxycholate and miltefosine which were used as a positive control for comparison of the antileishmanial activities of the test compounds, were also made in three fold serial dilutions (Foroumadi et al., 2005).

**Biological activity test**

**In vitro antipromastigote assay**

Promastigote forms of L. donovani and standard drugs Amphotericin B deoxycholate and miltefosine were used for the assay. 3 × 10⁶ promastigotes of L. donovani in 100 µl were seeded to each well in a 96 well flat bottom plate. Various dilutions (10, 3.33, 1.11, 0.37, 0.12, and 0.04 µg ml⁻¹) of test compounds were added to the parasites. The tests were done in duplicates. Some of the wells contained only the standard drugs and served as a positive control. The media and DMSO alone were used as a negative control. The plates were kept at room temperature. After 24 h, 20 µl of Alamar blue (12.5 mg of resazurin dissolved in 100 ml of distilled water) (Yang et al., 2010) was added to each of the wells. Absorbance of the resulting mixture was measured after 48 h at a wavelength of 540 and 630 nm using Enzyme Linked Immuno Sorbent Assay (ELISA) plate reader (Al-Nasiry et al., 2007). A quantitative colorimetric assay using the oxidation-reduction indicator Alamar Blue was developed to measure cytotoxicity of the synthesized compounds against the protozoan parasite Leishmania donovani. The Alamar Blue assay permits a simple, reproducible and reliable method for screening antileishmanial drugs (Judith and Dietmar, 2001; Shimony and Jaffe, 2008; Nakayama et al., 1997).

**In vitro antileishmanial activity on L. aethiopica amastigotes**

In a 96-well microtitre plate, test substances were serially diluted to final test concentrations of 0.04 to 10 µg ml⁻¹ in 50 µl culture medium and 50 µl suspensions of axenic amastigotes containing 2 × 10⁷ cells/ml were added to each well. Contents of the plates were then incubated in humidified atmosphere containing 5% CO₂ at 31°C for 72 h. After 68 h of incubation, 10 µl of fluorochrome resazurin solution (12.5 µg dissolved in 100 ml of PBS pH=7.2) was added into each well and the fluorescence intensity was measured after a total incubation time of 72 h using 37 Victor 3 Multilabel Counter at excitation wavelength of 530 nm and emission wavelength of 590 nm. The IC₅₀ (µg ml⁻¹) values for each extract were evaluated from sigmoidal dose-response curves using computer software Graph pad prism 3.0 and values expressed as mean ± standard [SD] of triplicate experiments with each test concentration in duplicate. Assays with standard antileishmanial drugs and negative controls (medium alone and 1% DMSO) were also performed to have reference values. Also the background fluorescence intensity of each extract, essential oil and reference drug were measured (Habtemariam, 2003).

**Data analysis**

The IC₅₀ values for synthesized compounds tested for their in vitro antileishmanial activity were evaluated from sigmoidal dose-response curves using non linear regression software (GraphPad Prism®; GraphPad Software, Inc., San Diego, CA).

**RESULTS AND DISCUSSION**

**Biological assays**

**In vitro antipromastigote activity**

The antipromastigote assay of the synthesized compounds was carried out according to the method described in the experimental part. The results obtained were analyzed and IC₅₀ (µg ml⁻¹) for each test compound was calculated using Graph pad prism software (Table 1). The result revealed that the synthesized compounds except compound IIb possess better antileishmanial activity than the standard drug miltefosine which has IC₅₀ value 3.1911 µg ml⁻¹. However, synthesized compounds except for compounds III and IIIb exhibited lower antileishmanial activity compared to the standard amphotericin B deoxycholate (IC₅₀ = 0.0460 µg ml⁻¹). Compound IIIb, the phenyl pyrazoline with propanoyl side chain, was found to be the most active (IC₅₀ = 0.0112 µg ml⁻¹) compound as compared to the standard miltefosine (IC₅₀ = 3.1911 µg ml⁻¹) and amphotericin B deoxycholate.

<table>
<thead>
<tr>
<th>Test compound</th>
<th>Activity IC₅₀ (µgml⁻¹)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antipromastigote</td>
</tr>
<tr>
<td>Compound II</td>
<td>3.1143</td>
</tr>
<tr>
<td>Compound IIA</td>
<td>2.0730</td>
</tr>
<tr>
<td>Compound IIb</td>
<td>6.5310</td>
</tr>
<tr>
<td>Compound IIc</td>
<td>0.1673</td>
</tr>
<tr>
<td>Compound III</td>
<td>0.0422</td>
</tr>
<tr>
<td>Compound IIIa</td>
<td>1.3076</td>
</tr>
<tr>
<td>Compound IIIb</td>
<td>0.0112</td>
</tr>
<tr>
<td>Miltefosine</td>
<td>3.1911</td>
</tr>
<tr>
<td>Amphotericin B deoxycholate</td>
<td>0.0460</td>
</tr>
</tbody>
</table>

IC₅₀ values indicate the effective concentration of a compound required to achieve 50 % growth inhibition in µg/ml.

Table 1. Antipromastigote and antiamastigote activity (IC₅₀ µgml⁻¹) of the test compounds and reference standards.
(IC_{50} = 0.0460 \text{ µg mL}^{-1}). Compared to study done by Vikramdeep et al. (2014) and Manuel et al. (2012), this research reveal that the phenyl pyrazoline derivative compound III and IIIb have better antileishmanial activity with IC_{50} value of 0.0422 and 0.0112 \text{ µg mL}^{-1}, respectively. This might be due to the formation of hydrogen bonding between its carbonyl group and backbone of certain receptor active site in the former compound III, and the presence of propanoyl group in the latter compound IIIb, may play a role in the interaction with vital important biochemical process. The thienyl pyrazoline derivative, 1-phenyl-4-(3-thiophen-2-yl)-4,5-dihydro-1H-pyrazol-5-yl)-3-p-tolyl-1H-pyrazole (compound IIc) the non-substituted compound IIc (IC_{50} = 0.1673 \text{ µg mL}^{-1}) seems to affect positively the biological activity leading to the better antileishmanial activity when compared with ethanoyl (CH_{2}CO-) compound IIa and propanoyl (CH_{2}CH_{2}CO-) compound IIIb substituted compound and study done by Pinheiro et al. (2012).

The phenyl derivative displayed better activity than the corresponding thienyl derivatives for leishmania activity. Regarding the thienyl derivatives of the pyrazolines, activity decreased with the increase in the carbon number of aliphatic substitution at pyrazoline N1 from H to propanoyl group. However, the activity increased with increasing the length of the side chain in the phenyl pyrazolines. This could be attributed to the associated increase in hydrophobicity of the compounds that increases hydrophobic interaction with the molecular target site.

In vitro antiamastigote activity

The antiamastigote assay of the synthesized compounds, standard drug miltefosine and amphotericin B deoxycholate on L. aethiopica was carried out according to the method described in the experimental part. The results obtained were analyzed and IC_{50} for each test compound was calculated using Graph pad prism software (Table 1). The result showed that the synthesized compounds except for compounds III (IC_{50} = 0.28±0.03 \text{ µg mL}^{-1}), possess lower antileishmanial activity than the standard drug miltefosine and amphotericin B deoxycholate that have IC_{50} value 0.3±0.04 and 0.2±0.02 \text{ µg mL}^{-1}, respectively. Compound IIIb which exhibited the highest antipromastigote activity, has shown the least antiamastigote activity, while compound III has almost comparable activity with the standard drug miltefosine and amphotericin B deoxycholate.

Conclusion

Seven pyrazole derivatives were synthesized using aldol condensation and subsequent cyclization reactions in a good yield (71.39 to 95.20%). The compounds were purified with recrystallization method and were characterized by elemental microanalysis, IR, and 1H NMR spectroscopy. In vitro antileishmanial activity was conducted using Alamar blue reduction method and the results revealed that synthesized compounds showed better antileishmanial activity than the standard drug miltefosine. But all the synthesized compounds except for compounds III and IIIb exhibited lower antileishmanial activity compared with the standard amphotericin B deoxycholate.

Moreover, the phenyl pyrazolines showed better antileishmanial activity compared with the thienyl pyrazolines and their activity increased with increased number of carbons in the side chain. Compound IIIb, 1-(3-phenyl-5-(1-phenyl-3-p-tolyl-1H-pyrazol-4-yl)-4,5-dihydropyrazol-1-yl)propan-1-one phenyl pyrazoline, is found to be the most active (IC_{50} = 0.0112 \text{ µg mL}^{-1}) and this compound could represent a fruitful matrix for the development of antileishmanial agents that would deserve further derivatization and investigation. Among seven synthesized compounds, compounds III is found to be the most active (IC_{50} = 0.28±0.03 \text{ µg mL}^{-1}) and has comparable antileishmanial activity to the standard miltefosine and amphotericin B deoxycholate on L. aethiopica amastigotes.

Conflict of Interests

The authors have not declared any conflict of interests.

REFERENCES


